Recent investigations have centered on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopaminergic signaling. While GIP agonists are commonly employed for treating type 2 T2DM, their unexpected consequences on reward circuits, specifically influenced by dopaminergic pathways, are attracting substantial interest. This paper… Read More